188 related articles for article (PubMed ID: 26702066)
1. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Mato AR; Islam P; Daniel C; Strelec L; Kaye AH; Brooks S; Ganetsky A; Nasta S; Porter DL; Svoboda J; Nabhan C; Schuster SJ
Blood; 2016 Feb; 127(8):1064-7. PubMed ID: 26702066
[No Abstract] [Full Text] [Related]
2. Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
Giovanni B; Ibatici A; Sola S; Brunasso AMG; Massone C
Am J Dermatopathol; 2020 Feb; 42(2):148-150. PubMed ID: 30839345
[No Abstract] [Full Text] [Related]
3. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
[No Abstract] [Full Text] [Related]
4. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
5. Ibrutinib-Induced Neutrophilic Dermatosis.
El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
7. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
8. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
9. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
[No Abstract] [Full Text] [Related]
10. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
11. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM; Hwang CK; Kim BJ
J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
[TBL] [Abstract][Full Text] [Related]
12. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Jones JA; Hillmen P; Coutre S; Tam C; Furman RR; Barr PM; Schuster SJ; Kipps TJ; Flinn IW; Jaeger U; Burger JA; Cheng M; Ninomoto J; James DF; Byrd JC; O'Brien SM
Br J Haematol; 2017 Jul; 178(2):286-291. PubMed ID: 28397242
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
14. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
Majcherek M; Dworacka M; Dworacki G
Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
[TBL] [Abstract][Full Text] [Related]
15. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
16. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
17. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
18. Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.
Roeker LE; Sarraf Yazdy M; Rhodes J; Goodfriend J; Narkhede M; Carver J; Mato A
JAMA Netw Open; 2019 Dec; 2(12):e1916326. PubMed ID: 31790561
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
20. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]